Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings

1 Sept 2018

Abstract excerpt

BACKGROUND: Outcomes of tailoring statin-type based on solute carrier organic anion transporterfamily member 1B1 ( SLCO1B1)pharmacogenetic toxicity information on patient, provider, and pharmacological outcomes are unknown. METHODS: The trial randomized 159 patients not taking statins because of prior statin myalgia 1:1 to receiving SLCO1B1 GIST (Genotype Informed Statin Therapy) versus usual care (UC) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Transport and Resistance Mechanisms
Share to Lipoproteins and Cardiovascular Health
Share to Parathyroid Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30354330
DOI: 10.1161/circgen.118.002228

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational SettingsPMID 30354330Read ↗

SLCO1B1 Exome Sequencing and Statin Treatment Response in 64,000 UK Biobank Patients.Semantic proximity Read ↗

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.Semantic proximity Read ↗

Evaluating genotype-treatment interactions for high-risk medications in British general practice: a retrospective cohort study using UK Biobank.Semantic proximity Read ↗

Comparative Analysis of Atorvastatin and Rosuvastatin Side Events and Risk Factors in the UAE Multiethnic Population: Focus on Pharmacogenomic VariantsSemantic proximity Read ↗

Predictive value of<i>SLCO1B1</i>c.521T>C polymorphism on observed changes in the treatment of 1136 statin-usersSemantic proximity Read ↗

Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A 2x2 Factorial Mendelian Randomization StudySemantic proximity Read ↗

Understanding the causes and consequences of low statin adherence: evidence from UK Biobank primary care dataSemantic proximity Read ↗

SLCO1B1 Functional Variants, Bilirubin, Statin-Induced Myotoxicity, and Recent Sub-Saharan African Ancestry: A Precision Medicine Health Equity Study.Semantic proximity Read ↗

Veterans Health Administration: Implementation of pharmacogenomic clinical decision support with statin medications and the SLCO1B1 gene as an exemplarSemantic proximity Read ↗

Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users.Semantic proximity Read ↗

Genetic Determinants of Statin-induced Myopathy: A Network Meta-analysis of Observational Studies.Semantic proximity Read ↗

Pharmacogenomic insights into atorvastatin and rosuvastatin adverse effects: a prospective observational study in the UAE's multiethnic population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.